marked.bio

MET inhibitor · small molecule

elzovantinib

1 active trials, targeting MET/SRC/CSF1R. Not approved for any biomarker on marked.bio yet.

Also known as TPX-0022.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
MET exon 14 skipping 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of elzovantinib.

  1. Bristol Myers Squibb 1

Trials

1 of 1 trials shown

  1. Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

    Active, not recruiting Phase 1 Bristol Myers Squibb Started 2019Primary completion 2024-01 NCT03993873

    elzovantinib

    Histological or cytological confirmation of advanced/metastatic MET exon 14 skipping mutation (METΔex14) NSCLC, MET amplified NSCLC, or MET amplified gastric cancers…

    MET exon 14 skippingAdvanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations